Lastly, using antisense oligonucleotides that potently but transiently reduce TREM2 expression at late stages of plaque pathology significantly reduced plaque deposition and microglia association around plaque deposits, indicating a time- and/or dose-dependent intervening the TREM2 signaling for the therapy of AD.540. Here, TREM2 is linked to Alzheimer disease.